BridgeBio Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2834 http://bridgebio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma Inc

BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate - May 26th, 2022 5:38 pm
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias - May 26th, 2022 5:00 pm
BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder - May 20th, 2022 7:04 pm
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - May 20th, 2022 11:30 am
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates - May 18th, 2022 3:41 pm
BridgeBio Pharma to Participate in May Investor Events - May 17th, 2022 11:30 am
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor - May 13th, 2022 6:29 pm
10 Amazing Stocks Under $10 (Part II) - May 13th, 2022 2:35 pm
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years - May 13th, 2022 11:30 am
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology - May 12th, 2022 1:48 pm
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology - May 12th, 2022 11:30 am
What Does The Future Hold For BridgeBio Pharma, Inc. (NASDAQ:BBIO)? These Analysts Have Been Cutting Their Estimates - May 12th, 2022 10:13 am
BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference - May 10th, 2022 8:30 pm
BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative' - May 5th, 2022 7:37 pm
BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates - May 5th, 2022 12:45 pm
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update - May 5th, 2022 11:30 am
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - May 4th, 2022 10:05 pm
BridgeBio Pharma (BBIO) Stock Sinks As Market Gains: What You Should Know - Apr 28th, 2022 10:15 pm
BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Apr 3rd, 2022 12:36 pm
BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo - Mar 28th, 2022 11:30 am